Chromatin Structure and Drug Resistance in Candida spp.
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Anti-microbial resistance (AMR) is currently one of the most serious threats to global human health and, appropriately, research to tackle AMR garnishes significant investment and extensive attention from the scientific community. However, most of this effort focuses on antibiotics, and research into anti-fungal resistance (AFR) is vastly under-represented in comparison. Given the growing number of vulnerable, immunocompromised individuals, as well as the positive impact global warming has on fungal growth, there is an immediate urgency to tackle fungal disease, and the disturbing rise in AFR. Chromatin structure and gene expression regulation play pivotal roles in the adaptation of fungal species to anti-fungal stress, suggesting a potential therapeutic avenue to tackle AFR. In this review we discuss both the genetic and epigenetic mechanisms by which chromatin structure can dictate AFR mechanisms and will present evidence of how pathogenic yeast, specifically from the Candida genus, modify chromatin structure to promote survival in the presence of anti-fungal drugs. We also discuss the mechanisms by which anti-chromatin therapy, specifically lysine deacetylase inhibitors, influence the acquisition and phenotypic expression of AFR in Candida spp. and their potential as effective adjuvants to mitigate against AFR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · cited 1×
“Regardless, it is pertinent to remember that not all KDACs target histone-related processes [173] and the treatment with KDACIs may have other, unrelated effects.”
BackgroundSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
Persistent bacterial infections and persister cells
Fisher, R. A., Gollan, B., & Helaine, S. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.42 · Cited by 1,243 · cited 2×
“The idea has long been described for bacteria, where persister cells are a phenotypically distinct population of cells that are resistant to antibiotics, despite being genetically identical to their antibiotic susceptible counterparts [99,100].”
BackgroundCandida albicans Biofilms and Human Disease
Nobile, C. J., & Johnson, A. D. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104330 · Cited by 1,057
Vermes, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.171 · Cited by 803
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718 · cited 1×
“albicans Candida [NCAC] infections have progressively increased in frequency over the past two decades [2,7].”
BackgroundMultidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
Candida Biofilms: Threats, Challenges, and Promising Strategies
Cavalheiro, M., & Teixeira, M. C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00028 · Cited by 690
Chromatin organization is a major influence on regional mutation rates in human cancer cells
Schuster-Böckler, B., & Lehner, B. (2012) · Nature · doi:10.1038/nature11273 · Cited by 657 · cited 1×
“For example, there is a positive correlation between somatic mutation rate and densely packed DNA in human tumor cells [54].”
BackgroundMechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642 · cited 3×
“Realistically, the anti-fungal drug tolerant state is multifactorial and as such, improved experimental design, methods and data interpretation, using guidelines set out by Berman and Krysan [81], will help delineate between the epigenetic and genetic contributions.”
BackgroundMethodEpidemiology and risk factors for invasive candidiasis
Yapar, N. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s40160 · Cited by 610 · cited 1×
“glabrata is the most frequently isolated NCAC species in global surveillance studies, representing 10-18% of all Candida isolates [8].”
BackgroundDrinnenberg, I. A., Weinberg, D. E., Xie, K. T., Mower, J. P., Wolfe, K. H., Fink, G. R., & Bartel, D. P. (2009) · Science · doi:10.1126/science.1176945 · Cited by 524
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523 · cited 1×
“Although it is known that VPA selectively targets HDAC2 in human cells [172], this remains to be confirmed for the homologous Candida proteins, Hos2p and Hos3p.”
BackgroundCandida albicans Biofilms Produce Antifungal-Tolerant Persister Cells
LaFleur, M. D., Kumamoto, C. A., & Lewis, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00684-06 · Cited by 521
Ramage, G. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf049 · Cited by 468
Mechanisms of Candida Biofilm Drug Resistance
Taff, H. T., Mitchell, K. F., Edward, J. A., & Andes, D. R. (2013) · Future Microbiology · doi:10.2217/fmb.13.101 · Cited by 422
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
Multidrug-resistant endemic clonal strain of Candida auris in India
Chowdhary, A., Anil Kumar, V., Sharma, C., Prakash, A., Agarwal, K., Babu, R., Dinesh, K. R., Karim, S., Singh, S. K., Hagen, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2027-1 · Cited by 373
Estimating the Per-Base-Pair Mutation Rate in the Yeast Saccharomyces cerevisiae
Lang, G. I., & Murray, A. W. (2008) · Genetics · doi:10.1534/genetics.107.071506 · Cited by 344 · cited 1×
“It is known that: (i) mutation rate is not constant across the length of a Saccharomyces cerevisiae chromosome [55] and heterochromatic regions have a higher per base substitution rate [56]; (ii) there is a 10-15% reported lower substitution rate in inter-nucleosomal linker-DNA compared with nucleosomal DNA [57]; and…”
BackgroundRoger, T., Lugrin, J., Le Roy, D., Goy, G., Mombelli, M., Koessler, T., Ding, X. C., Chanson, A.-L., Reymond, M. K., Miconnet, I., et al. (2011) · Blood · doi:10.1182/blood-2010-05-284711 · Cited by 341 · cited 1×
“albicans infection model, evidently by the down-regulation of host innate immunity defense genes [165].”
BackgroundFitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322 · cited 1×
“The underlying molecular events that dictate this interspecies mutational bias in azole resistance remain unclear, but potentially evolutionary parameters, such as differences in fitness trade-off between the individual resistance mutations in each species, may account for these observations [52].”
BackgroundSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Fungal ß(1,3)-D-glucan synthesis
Douglas, C. M. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.55.66 · Cited by 312
Pande, K., Chen, C., & Noble, S. M. (2013) · Nature Genetics · doi:10.1038/ng.2710 · Cited by 306 · cited 1×
“For commensals and opportunistic strains, switching phenotypes can serve to maximize the colonization of their human host [123,124] including strategies such as host immune avoidance [125,126].”
BackgroundPoised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301 · cited 2×
“Furthermore, although KDACIs could potentially be used to inhibit the emergence of acquired anti-fungal resistant clones, similar to what has been seen in using epigenetic-based anti-cancer therapy [86], this effect may depend on the starting epigenetic state of a given isolate, which paradoxically may reflect its gen…”
BackgroundA Candida Biofilm-Induced Pathway for Matrix Glucan Delivery: Implications for Drug Resistance
Taff, H. T., Nett, J. E., Zarnowski, R., Ross, K. M., Sanchez, H., Cain, M. T., Hamaker, J., Mitchell, A. P., & Andes, D. R. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002848 · Cited by 291 · cited 3×
“Biofilm phenotypic resistance is due to numerous mechanisms including, but not limited to, drug sequestration by the biofilm matrix [96] and up-regulation of drug efflux pumps, [97] both of which result in lower intracellular concentrations of the anti-fungal drug.”
BackgroundSanglard, D., Coste, A., & Ferrari, S. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00578.x · Cited by 285
Vermitsky, J.-P., & Edlind, T. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3773-3781.2004 · Cited by 285 · cited 1×
“glabrata is the acquisition of mutations in the Cg_PDR1 transcription factor gene that regulates the expression of the Cg_Cdr1p drug efflux pump [47,50,51].”
BackgroundMetabolic specialization associated with phenotypic switching in Candida albicans
Lan, C.-Y., Newport, G., Murillo, L. A., Jones, T., Scherer, S., Davis, R. W., & Agabian, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232566499 · Cited by 275 · cited 1×
“albicans opaque cell phenotype is metabolically less active than the default white state under a variety of growth conditions, including under stress [139,140].”
BackgroundRosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270 · cited 3×
“Similar to other phenotypic resistant states, evidence suggests that Candida tolerance is mediated by the up-regulation of efflux pumps in tolerant cells [143], or potentially an increase in cell wall chitin in tolerant cells, which limits drug uptake [146].”
BackgroundPatients with Long-Term Oral Carriage Harbor High-Persister Mutants of Candida albicans
LaFleur, M. D., Qi, Q., & Lewis, K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00860-09 · Cited by 237
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
Elevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01486-12 · Cited by 214 · cited 1×
“Similar to other phenotypic resistant states, evidence suggests that Candida tolerance is mediated by the up-regulation of efflux pumps in tolerant cells [143], or potentially an increase in cell wall chitin in tolerant cells, which limits drug uptake [146].”
BackgroundPhenotypic Resistance to Antibiotics
Corona, F., & Martinez, J. (2013) · Antibiotics · doi:10.3390/antibiotics2020237 · Cited by 205
Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy
Wurtele, H., Tsao, S., Lépine, G., Mullick, A., Tremblay, J., Drogaris, P., Lee, E.-H., Thibault, P., Verreault, A., & Raymond, M. (2010) · Nature Medicine · doi:10.1038/nm.2175 · Cited by 157
Global analysis of mutations driving microevolution of a heterozygous diploid fungal pathogen
Ene, I. V., Farrer, R. A., Hirakawa, M. P., Agwamba, K., Cuomo, C. A., & Bennett, R. J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1806002115 · Cited by 155 · cited 2×
“Both studies also reveal the inconsistency of acquired genetic variation and how genome characteristics, such as differences in ploidy [68] and sub-telomeric chromatin structures [67], disproportionately elevate mutation mate.”
BackgroundSmith, W. L., & Edlind, T. D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3532-3539.2002 · Cited by 147
Pfaller, M. A., Messer, S. A., Georgopapadakou, N., Martell, L. A., Besterman, J. M., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00618-09 · Cited by 143
Fungal persister cells: The basis for recalcitrant infections?
Wuyts, J., Van Dijck, P., & Holtappels, M. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007301 · Cited by 136 · cited 2×
“This is especially true for fungal persister cells, which are thought to be in an inactive dormant state [87].”
BackgroundHistone acetyltransferase Rtt109 is required for Candida albicans pathogenesis
Lopes da Rosa, J., Boyartchuk, V. L., Zhu, L. J., & Kaufman, P. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912427107 · Cited by 132
Hnisz, D., Majer, O., Frohner, I. E., Komnenovic, V., & Kuchler, K. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000889 · Cited by 124 · cited 3×
“albicans transcriptome is dependent on the function of the histone deacetylase complex SET3C, which modulates transient expression changes of key morphogenesis-related genes [106,107].”
BackgroundCandida albicans biofilms: building a heterogeneous, drug-tolerant environment
Bonhomme, J., & d’Enfert, C. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.03.007 · Cited by 120
Defining the frontiers between antifungal resistance, tolerance and the concept of persistence
Delarze, E., & Sanglard, D. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.001 · Cited by 118
Hnisz, D., Bardet, A. F., Nobile, C. J., Petryshyn, A., Glaser, W., Schöck, U., Stark, A., & Kuchler, K. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003118 · Cited by 100
Absence of Amphotericin B-Tolerant Persister Cells in Biofilms of Some Candida Species
Al-Dhaheri, R. S., & Douglas, L. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01473-07 · Cited by 99
A Histone Deacetylase Complex Mediates Biofilm Dispersal and Drug Resistance in Candida albicans
Nobile, C. J., Fox, E. P., Hartooni, N., Mitchell, K. F., Hnisz, D., Andes, D. R., Kuchler, K., & Johnson, A. D. (2014) · mBio · doi:10.1128/mbio.01201-14 · Cited by 87 · cited 1×
“albicans biofilms formed by cells lacking SET3C function have altered physical characteristics compared to WT cells, including increased biomass, enhanced cohesiveness and, most importantly, increased phenotypic resistance [109].”
BackgroundSellam, A., Askew, C., Epp, E., Lavoie, H., Whiteway, M., & Nantel, A. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-11-1093 · Cited by 87
Spettel, K., Barousch, W., Makristathis, A., Zeller, I., Nehr, M., Selitsch, B., Lackner, M., Rath, P.-M., Steinmann, J., & Willinger, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210397 · Cited by 86
Lu, Y., Su, C., Mao, X., Raniga, P. P., Liu, H., & Chen, J. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-02-0173 · Cited by 82
Apoptosis in Candida biofilms exposed to amphotericin B
Al-Dhaheri, R. S., & Douglas, L. J. (2010) · Journal of Medical Microbiology · doi:10.1099/jmm.0.015784-0 · Cited by 81
Function and subcellular localization of Gcn5, a histone acetyltransferase in Candida albicans.
Chang, P., Fan, X., & Chen, J. (2015) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2015.01.011 · Cited by 73 · cited 1×
“Consistently, deletion of the catalytic subunit of SAGA (Ca_gcn5∆/∆) leads to a severe morphogenesis defect and lack of hyphal formation [40,116].”
BackgroundPfaller, M. A., Rhomberg, P. R., Messer, S. A., & Castanheira, M. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.11.008 · Cited by 67 · cited 1×
“albicans, NCAC species, and non-Candida fungal pathogens [168,169].”
BackgroundThe Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans
Li, X., Cai, Q., Mei, H., Zhou, X., Shen, Y., Li, D., & Liu, W. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv070 · Cited by 64
Orta‐Zavalza, E., Guerrero‐Serrano, G., Gutiérrez‐Escobedo, G., Cañas‐Villamar, I., Juárez‐Cepeda, J., Castaño, I., & De Las Peñas, A. (2013) · Molecular Microbiology · doi:10.1111/mmi.12247 · Cited by 61
Rueda, C., Puig-Asensio, M., Guinea, J., Almirante, B., Cuenca-Estrella, M., Zaragoza, O., Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J. R., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.016 · Cited by 58 · cited 1×
“Although the clinical relevance of the trailing phenotype is under debate [144], such anti-fungal tolerant cells are readily isolated from patients with persistent candidemia [143] and those with prolonged C.”
BackgroundShivarathri, R., Tscherner, M., Zwolanek, F., Singh, N. K., Chauhan, N., & Kuchler, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-45817-5 · Cited by 58 · cited 3×
“unaltered azole susceptibility but hyper-s n itivity to caspofungin [40].”
BackgroundResultTscherner, M., Zwolanek, F., Jenull, S., Sedlazeck, F. J., Petryshyn, A., Frohner, I. E., Mavrianos, J., Chauhan, N., von Haeseler, A., & Kuchler, K. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005218 · Cited by 57
Fonseca, E., Silva, S., Rodrigues, C. F., Alves, C. T., Azeredo, J., & Henriques, M. (2014) · Biofouling · doi:10.1080/08927014.2014.886108 · Cited by 56
Fungal KATs/KDACs: A New Highway to Better Antifungal Drugs?
Kuchler, K., Jenull, S., Shivarathri, R., & Chauhan, N. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005938 · Cited by 40 · cited 2×
“Therefore, it is no surprise that the therapeutic potential of KDACIs to combat fungal disease has been explored [31,149].”
BackgroundScope and frequency of fluconazole trailing assessed using EUCAST in invasive Candida spp. isolates
Marcos-Zambrano, L. J., Escribano, P., Sánchez-Carrillo, C., Bouza, E., & Guinea, J. (2016) · Medical Mycology · doi:10.1093/mmy/myw033 · Cited by 33
Candida albicans Biofilms Are Generally Devoid of Persister Cells
Denega, I., d’Enfert, C., & Bachellier-Bassi, S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01979-18 · Cited by 32
Candida glabrata's recurrent infections: biofilm formation during Amphotericin B treatment
Rodrigues, C. F., Silva, S., Azeredo, J., & Henriques, M. (2016) · Letters in Applied Microbiology · doi:10.1111/lam.12600 · Cited by 21
Zomorodian, K., Bandegani, A., Mirhendi, H., Pakshir, K., Alinejhad, N., & Poostforoush Fard, A. (2016) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.28666 · Cited by 20 · cited 1×
“Such trialing growth has been described for multiple Candida species [141] and is detected in up to 60% of C.”
BackgroundHnisz, D., Tscherner, M., & Kuchler, K. (2011) · Epigenomics · doi:10.2217/epi.11.7 · Cited by 14
Cited by
Transcriptional and translational landscape of Candida auris in response to caspofungin
Zamith-Miranda, D., Amatuzzi, R. F., Munhoz da Rocha, I. F., Martins, S. T., Lucena, A. C. R., Vieira, A. Z., Trentin, G., Almeida, F., Rodrigues, M. L., Nakayasu, E. S., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.09.007 · Cited by 29
“5273 modifiers can affect drug resistance [50].”
Histone Acetylation Regulator Gcn5 Mediates Drug Resistance and Virulence of Candida glabrata
Yu, S., Paderu, P., Lee, A., Eirekat, S., Healey, K., Chen, L., Perlin, D. S., & Zhao, Y. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00963-22 · Cited by 23
El Meouche, I., Jain, P., Jolly, M. K., & Capp, J.-P. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102069 · Cited by 22
Moirangthem, R., Kumar, K., & Kaur, R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02415-20 · Cited by 20
Metadata
- Authors
- O’Kane, C. J., Weild, R., & M. Hyland, E.
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2020-07-30
- Volume
- 6
- Issue
- 3
- Pages
- 121
- ISSN
- 2309-608X (ISSN-L)
- OpenAlex
- W3045715566
- Cited by
- 18
- References
- 68
- FWCI
- 0.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.